ReShape Lifesciences Inc. (NASDAQ:RSLS), formerly EnteroMedics Inc., is a medical device company focused on the development of minimally invasive medical devices to treat obesity and metabolic diseases. ReShape Lifesciences™ is committed to the delivery of safe, effective, and sustainable obesity solutions. The company is rapidly advancing its innovative technologies to broadly benefit patients, healthcare providers, and stakeholders around the world.

ReShape vBloc, delivered by an FDA-approved pacemaker-like device, is designed to help patients with a Body Mass Index (BMI) of 40-45, or 35-39.9 with a minimum of one related comorbid condition, feel full, eat less and lose weight by intermittently blocking hunger signals on the vagus nerve.